Your browser doesn't support javascript.
loading
Exploring High-Throughput Immunoassays for Biomarker Validation in Rheumatic Diseases in the Context of the Human Proteome Project.
Fuentes, Manuel; Ruiz-Romero, Cristina; Misiego, Sara; Juanes-Velasco, Pablo; Landeira-Viñuela, Alicia; Torres-Roda, Adrián; Lorenzo-Gil, Héctor; González-González, María; Hernández, Ángela P; Lourido, Lucía; Sjöberg, Ronald; Pin, Elisa; de Las Rivas, Javier; Sánchez-Santos, José Manuel; Nilsson, Peter; Blanco, Francisco J.
Affiliation
  • Fuentes M; Department of Medicine and General Cytometry Service-Nucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007Salamanca, Spain.
  • Ruiz-Romero C; Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007Salamanca, Spain.
  • Misiego S; Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. C/As Xubias de Arriba 84, 15006A Coruña, Spain.
  • Juanes-Velasco P; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Av. Monforte de Lemos, 3-5. Pabellón 11, 28029Madrid, Spain.
  • Landeira-Viñuela A; Department of Medicine and General Cytometry Service-Nucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007Salamanca, Spain.
  • Torres-Roda A; Department of Medicine and General Cytometry Service-Nucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007Salamanca, Spain.
  • Lorenzo-Gil H; Department of Medicine and General Cytometry Service-Nucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007Salamanca, Spain.
  • González-González M; Department of Medicine and General Cytometry Service-Nucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007Salamanca, Spain.
  • Hernández ÁP; Department of Medicine and General Cytometry Service-Nucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007Salamanca, Spain.
  • Lourido L; Department of Medicine and General Cytometry Service-Nucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007Salamanca, Spain.
  • Sjöberg R; Department of Medicine and General Cytometry Service-Nucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007Salamanca, Spain.
  • Pin E; Department of Pharmaceutical Sciences: Organic Chemistry, Faculty of Pharmacy, University of Salamanca, CIETUS, IBSAL, 37007Salamanca, Spain.
  • de Las Rivas J; Unidad de Proteómica, Grupo de Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. C/As Xubias de Arriba 84, 15006A Coruña, Spain.
  • Sánchez-Santos JM; Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, 114 28Stockholm, Sweden.
  • Nilsson P; Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, 114 28Stockholm, Sweden.
  • Blanco FJ; Bioinformatics and Functional Genomics Research Group, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007Salamanca, Spain.
J Proteome Res ; 22(4): 1105-1115, 2023 04 07.
Article in En | MEDLINE | ID: mdl-36475733
Rheumatic diseases are high prevalence pathologies with different etiology and evolution and low sensitivity in clinical diagnosis. Therefore, it is necessary to develop an early diagnosis method which allows personalized treatment, depending on the specific pathology. The biology/disease initiative, at Human Proteome Project, is an integrative approach to identify relevant proteins in the human proteome associated with pathologies. A previously reported literature data mining analysis, which identified proteins related to osteoarthritis (OA), rheumatoid arthritis (RA), and psoriatic arthritis (PSA) was used to establish a systematic prioritization of potential biomarkers candidates for further evaluation by functional proteomics studies. The aim was to study the protein profile of serum samples from patients with rheumatic diseases such as OA, RA, and PSA. To achieve this goal, customized antibody microarrays (containing 151 antibodies targeting 121 specific proteins) were used to identify biomarkers related to early and specific diagnosis in a screening of 960 serum samples (nondepleted) (OA, n = 480; RA, n = 192; PSA, n = 288). This functional proteomics screening has allowed the determination of a panel (30 serum proteins) as potential biomarkers for these rheumatic diseases, displaying receiver operating characteristics curves with area under the curve values of 80-90%.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteoarthritis / Arthritis, Rheumatoid / Arthritis, Psoriatic / Rheumatic Diseases Type of study: Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Humans Language: En Journal: J Proteome Res Journal subject: BIOQUIMICA Year: 2023 Type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteoarthritis / Arthritis, Rheumatoid / Arthritis, Psoriatic / Rheumatic Diseases Type of study: Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Humans Language: En Journal: J Proteome Res Journal subject: BIOQUIMICA Year: 2023 Type: Article Affiliation country: Spain